Multiple ascending dose study of BMS‐790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1
Richard E. Nettles, Min Gao, Marc Bifano, Ellen Chung, Anna Persson, Thomas C. Marbury, Ronald Goldwater, Michael P. DeMicco, Maribel Rodriguez‐Torres, Apinya Vutikullird, Ernesto Fuentes, Eric Lawitz, Juan Carlos Lopez‐Talavera, Dennis M. Grasela – 2 December 2011 – The antiviral activity, resistance profile, pharmacokinetics (PK), safety, and tolerability of BMS‐790052, a nonstructural protein 5A (NS5A) replication complex inhibitor, were evaluated in a double‐blind, placebo‐controlled, sequential panel, multiple ascending dose study.